In vitro study of Seraspenide on HIV-induced inhibition of granulopoiesis.
Soluble(s) factor(s) produced by HIV-infected cells have been implicated in bone marrow dysfunction observed in AIDS patients. We have shown previously that infected macrophage but not CBMC-derived conditioned medium inhibited the differentiation of purified CD34+ cells, suggesting that accessory cells play a crucial role in granulopoiesis inhibition induced indirectly by HIV. In order to prevent this inhibition we tested the potential protective effect of Seraspenide, a reversible inhibitor of hematopoietic progenitors. We showed that 20 h pretreatment of mononuclear cells with Seraspenide at 10(-10) mol/l prevents CFU-GM inhibition induced by HIV-infected cell-derived conditioned medium.
Coutton
C
C
INSERM U322, Unit of Retroviruses and Associated Diseases, Marseille, France.
Chermann
J C
JC
D018952:Antigens, CD34 / Q000032:analysis; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D017077:Culture Media, Conditioned / Q000494:pharmacology; D006098:Granulocytes / Q000187:drug effects*; D006131:Growth Inhibitors / Q000494:pharmacology*; D015658:HIV Infections / Q000276:immunology*; D006410:Hematopoiesis / Q000187:drug effects*; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000821:virology; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000378:metabolism / Q000821:virology*; D009842:Oligopeptides / Q000494:pharmacology*; D016176:T-Lymphocyte Subsets / Q000737:chemistry
D018952:Antigens, CD34; D017077:Culture Media, Conditioned; D006131:Growth Inhibitors; D009842:Oligopeptides; C058504:goralatide